Health Care · NYSE: BDX
Becton Dickinson: how the business works
Becton Dickinson (BD) makes syringes, IV catheters, blood-collection tubes, infusion pumps and medicine-dispensing cabinets for hospitals, labs and drugmakers, with revenue of $19,457 million in FY2026.
By Hardik Bhandare · Checked against filings: . Editorial policy. Corrections
Follow Becton Dickinson
Email me when Becton Dickinson's page is updated after earnings.
We'll send a confirmation email first. See our privacy policy.
Becton, Dickinson and Company · Franklin Lakes, New Jersey · Founded 1897
Updated for Q4 FY2026 · checked
- Revenue, FY2026 (unaudited)
- $19.5B
- Net income, continuing operations, FY2026
- $1.4B
- Countries with plants outside the US, Sep 30, 2025
- 18
- Employees, Nov 2026
- More than 60,000
- Founded
- 1897
The short version
Becton Dickinson in 5 points
1 · What it sells
BD sells hospital disposables and equipment, with FY2026 revenue of $19,457 million: 34.5% from Medical Essentials, 28.6% Interventional, 24.4% Connected Care and 12.5% BioPharma Systems.
2 · Who pays it
BD names no single large customer and gives no split by customer type; by location, US customers paid 62% of FY2026 revenue and international customers 38%.
3 · What it keeps from $100
Of every $100 that came in during FY2026, BD kept $7.2 as net income from continuing operations after $4.1 of integration, restructuring and deal costs; operating income was $11.6 per $100 of revenue.
4 · Where the operating profit comes from
BD has not yet given FY2026 operating income by segment; by revenue, Medical Essentials was the largest at $6,703 million and Interventional grew fastest, up 6.8%.
5 · The one thing to watch
BD guided on Nov 5, 2026 to FY2027 adjusted diluted EPS of $13.10 to $13.30, against $12.70 in FY2026, after $806 million of integration, restructuring and deal costs in FY2026.
Sources: From BD's FY2025 10-K and its Q4 FY2026 earnings release of Nov 5, 2026 (unaudited) · checked
01Where the money goes · FY2026
Where does $100 of Becton Dickinson's money go?
Becton Dickinson · FY2026
Receipt for every $100
| Cost of making products | $52.3 |
|---|---|
| Selling and administration | $25.4 |
| Research and development | $5.0 |
| Integration, restructuring and deal costs | $4.1 |
| Other operating expenses | $1.0 |
| Interest on debt | $2.9 |
| Income tax | $2.0 |
| Kept as net income | $7.2 |
| Total | $100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly $100 because of rounding.
How this is worked out
Cityfort calculation from the Q4 FY2026 earnings release (unaudited). Of every $100 that came in during FY2026 (revenue of $19,457 million plus $113 million of interest and other income): each line = line ÷ $19,570 million × 100. Net income is from continuing operations; the $271 million loss from the business spun off to Waters is left out.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report earnings, explained in 5 points.
No tips. Unsubscribe anytime.
We'll send a confirmation email. See our privacy policy.
02The business in one line
What does Becton Dickinson do?
Hospitals, labs and drugmakers pay BD for disposable supplies and the pumps and cabinets that use them; making the products takes $52.3 of every $100, and $7.2 is left as net income.
- Medical Essentials, the syringes, catheters and tubes, was the largest segment at $6,703 million, or 34.5% of FY2026 revenue.
- Selling and administration took another $25.4 per $100, and integration, restructuring and deal costs $4.1.
- Since Feb 9, 2026 BD no longer owns its lab research and diagnostics business, which was combined with Waters.
03Who pays it
Who pays Becton Dickinson?
Hospitals and health systems
Share of revenue not disclosed
Buy disposables, mostly through distributors in the US, and buy or lease pumps and dispensing equipment, mostly sold direct.
Drug companies
12.5%
of revenue
Buy prefillable syringes for their injectable drugs; BioPharma Systems was 12.5% of FY2026 revenue.
Distributors
Share of revenue not disclosed
Acute care, non-acute care, laboratory and drug wholesalers resell BD disposables in the US; abroad BD sells direct or through distributors.
Labs and clinics
Share of revenue not disclosed
Buy blood-collection tubes and needles; Specimen Management sold $1,992 million in FY2026.
How spread out the customers are
No customer accounted for 10% or more of revenue in FY2023, FY2024 or FY2025, the FY2025 10-K says. BD does not give a split by customer type.
04How it makes money
How does Becton Dickinson make money?
BD earns by selling high volumes of low-cost disposables, plus equipment that keeps hospitals buying them.
Gross profit (revenue minus the cost of making products) per $100 of revenue rose from $44.5 in FY2025 to $47.4 in FY2026, both without the Waters business (Cityfort calculation from the Q4 FY2026 earnings release). Operating income is thinner, at $11.6 per $100 in FY2026, after selling, research and restructuring costs.
Gross profit per $100 of revenue
$44.5$47.4
FY2025 to FY2026
- A hospital installs BD pumps, dispensing cabinets or monitors
- Staff use BD disposables with that equipment every day
- Repeat orders flow through distributors
- Revenue pays for factories, research and new products
- New products are sold into the same hospitals
↺ Step 5 feeds back into step 1.
05Business segments · FY2026
Which businesses make up Becton Dickinson?
Medical Essentials
34.5%Syringes, IV catheters and blood-collection products; up 4.0% from $6,446 million in FY2025, recast without the Waters business.
Revenue $6.7B ($6,703M)
Interventional
28.6%Vascular, urology and surgery products; up 6.8%, the fastest of the four.
Revenue $5.6B ($5,573M)
Connected Care
24.4%Infusion pumps, dispensing and patient monitoring; up 4.1%.
Revenue $4.7B ($4,745M)
BioPharma Systems
12.5%Prefillable syringes for drugmakers; up 4.8%.
Revenue $2.4B ($2,437M)
How the mix changed
- Medical Essentials
- Interventional
- Connected Care
- BioPharma Systems
Revenue by segment, FY2025 to FY2026.
US$
See the numbers
06The numbers · Consolidated · US$
How has Becton Dickinson done?
Revenue
$19.5BFY2026
Revenue rose from $18,870 million in FY2022 to $21,840 million in FY2025 as first reported; FY2026 ($19,457 million, unaudited) and the quarters from Q2 FY2025 on (Q1 FY2026 as recast in April 2026) leave out the business spun off to Waters, while earlier rows include it.
* FY2026: After Waters spin-off; unaudited.
US$
See the numbers
Net income
$1.1BFY2026
Net income fell to $1,145 million in FY2026 from $1,678 million in FY2025, after $806 million of integration and restructuring costs and a $271 million loss from the spun-off business.
* FY2026: After Waters spin-off; unaudited.
US$
See the numbers
Net income for every $100 of revenue
$5.9FY2026
Net income per $100 of revenue stayed between $7.7 and $10.9 from FY2021 to FY2025 and was $5.9 in FY2026.
* FY2026: After Waters spin-off; unaudited.
Net margin: $ of net income per $100 of revenue
See the numbers
Free cash flow
$2.9BFY2026
Free cash flow (cash left after running and investing in the business) was $2,933 million in FY2026, against $2,058 million for FY2025 on the same continuing basis; the FY2025 bar ($2,670 million) includes the spun-off business.
* FY2026: After Waters spin-off; unaudited.
US$ · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own: Fiscal year ends Sep 30 (October to September). Net income is the share belonging to the company's owners.
Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained · Stock-based compensation and dilution: pay that becomes shares
Sources (16)
- Form 10-K for FY2023
- Form 10-K for FY2021
- Form 10-K for FY2022
- Form 10-K for FY2024
- Form 10-K for FY2025
- Q4 and full-year FY2026 earnings release (8-K Ex. 99.1)
- Form 10-Q for Q1 FY2024
- Form 10-Q for Q2 FY2024
- Form 10-Q for Q3 FY2024
- Form 10-Q for Q1 FY2025
- Form 10-Q for Q2 FY2026
- Form 10-Q for Q2 FY2025
- Form 10-Q for Q3 FY2026
- Form 10-Q for Q3 FY2025
- Form 10-Q for Q1 FY2026
- 8-K filed Apr 2, 2026: recast quarterly results for continuing operations after the Waters spin-off (Ex. 99.1)
07Who runs it
Who runs Becton Dickinson, and did they deliver?
Thomas E. Polen
Chairman, CEO and President · since 2020
CEO since early 2020 and Chairman since Apr 2021; earlier Chief Operating Officer.
Vitor Roque
Executive Vice President and CFO
Signed the Q1 FY2026 10-Q (Feb 9, 2026) as Interim CFO and the Q3 FY2026 10-Q (Aug 6, 2026) as EVP and CFO; the previous CFO, Christopher J. DelOrefice, left on Dec 5, 2025.
Michael Garrison
President, Medical Essentials and BioPharma Systems · since 2022
Said on Jul 19, 2026 that he would retire and stay in the role through the end of FY2026 (8-K filed Jul 22, 2026); BioPharma Systems will then report to Polen.
Richard Byrd
President, Interventional · since 2022
Earlier ran BD Medication Delivery Solutions.
Bilal Muhsin
President, Connected Care · since 2025
Joined in Jul 2025 from Masimo, where he was Chief Operating Officer.
What they said, and what happened
2 delivered · 1 too early to tell
Said on Feb 9, 2026
In its Q1 FY2026 release, BD guided to adjusted diluted EPS of $12.35 to $12.65 for FY2026 without the Waters business.
DeliveredWhat happened
The range was raised to $12.52–$12.72 on May 7 and $12.62–$12.72 on Aug 6, 2026; BD reported $12.70.
Said on Nov 25, 2025
The FY2025 10-K said BD expected about $4 billion in cash from the Waters deal, with its shareholders getting about 39.2% of the combined company.
DeliveredWhat happened
The deal closed on Feb 9, 2026; BD received $4 billion and its shareholders 39.2% of Waters on a fully diluted basis.
Said on Nov 5, 2026
On Nov 5, 2026 BD guided to FY2027 adjusted diluted EPS of $13.10 to $13.30 and low single-digit revenue growth.
Too early to tellWhat happened
FY2027 ends Sep 30, 2027.
Sources (10)
- Form 10-K for FY2025
- Proxy statement (DEF 14A) for the 2026 annual meeting
- Form 10-Q for Q1 FY2026
- Form 10-Q for Q3 FY2026
- 8-K filed Jul 22, 2026: officer retirement (Item 5.02)
- Q1 FY2026 earnings release (8-K Ex. 99.1)
- Q2 FY2026 earnings release (8-K Ex. 99.1)
- Q3 FY2026 earnings release (8-K Ex. 99.1)
- Q4 and full-year FY2026 earnings release (8-K Ex. 99.1)
- 8-K filed Feb 9, 2026: completion of the Biosciences and Diagnostic Solutions combination with Waters (Ex. 99.1)
08What could go wrong
What could go wrong for Becton Dickinson?
- Legal
Ethylene oxide lawsuits in Georgia
About 435 suits from about 445 people near its Covington sterilization site allege cancers and other injuries from ethylene oxide (Jun 30, 2026). In the first trial a jury awarded one plaintiff $20 million in compensatory damages in May 2025; no judgment has been entered, and BD's appeal of a trial-court ruling in the case was argued on May 14, 2026, the Q3 FY2026 10-Q says. BD says it has meritorious defenses.
Watch The Georgia Court of Appeals decision (argued May 14, 2026) and later trials.
- Regulation
FDA quality actions
Its infusion pumps operate under an FDA consent decree, and warning letters were issued to its San Diego dispensing site (Nov 2024) and El Paso plant (Apr 30, 2026). The 10-Q says the El Paso work added costs in Interventional.
Watch Any new FDA letter, recall or change to the consent decree.
- Debt
Debt level
Debt was $16,345 million at Sep 30, 2026 against $3,605 million of operating cash flow in FY2026. Its credit line caps leverage at 4.25 times.
Watch Debt at each quarter end and any change to its BBB / Baa2 ratings.
- Other
Tariffs
The Q3 FY2026 10-Q says tariffs hurt results and margins. The tariff relief in BD's Nov 5, 2026 US government deal depends on the final scope and on BD meeting agreed milestones.
Watch Gross profit per $100 of revenue each quarter and updates on the US investment plan.
- Pricing
Price pressure from hospitals and governments
The 10-K warns that merging health systems gain buying power and governments try to limit healthcare costs. Italy requires device makers to repay part of sales when regional budgets are exceeded; amounts for 2019 onward are unresolved.
Watch Revenue growth excluding currency, by segment.
- Execution
Separation and restructuring costs
Integration, restructuring and deal costs were $806 million in FY2026, double the $403 million in FY2025, and continuing operations lost $37 million in Q2 FY2026.
Watch Whether these costs fall in FY2027 results.
09Supporters vs. critics
What do supporters and critics point to?
What supporters point to
- All four segments grew in FY2026 on the continuing basis, led by Interventional at 6.8% and BioPharma Systems at 4.8%.
- Gross profit per $100 of revenue rose from $44.5 in FY2025 to $47.4 in FY2026, both without the Waters business (Cityfort calculation from the Q4 FY2026 release).
- Free cash flow was $2,933 million in FY2026, against $2,058 million for FY2025 on the same continuing basis.
- Debt fell to $16,345 million at Sep 30, 2026 from $19,179 million a year earlier. The Q3 FY2026 10-Q says about $2 billion of the Waters cash went to repaying debt.
- No customer reached 10% of revenue in FY2023 to FY2025, the FY2025 10-K says.
What critics point to
- Debt of $16,345 million at Sep 30, 2026 was about 4.5 years of FY2026 operating cash flow (Cityfort calculation from the Q4 FY2026 earnings release).
- About 435 suits in Georgia allege injuries from ethylene oxide at its Covington sterilization site (Jun 30, 2026); a jury awarded one plaintiff $20 million in compensatory damages in May 2025; no judgment has been entered, and BD's appeal of a trial-court ruling in the case was argued on May 14, 2026, the Q3 FY2026 10-Q says.
- Its infusion pumps operate under an FDA consent decree, and the FDA sent a warning letter on its El Paso plant on Apr 30, 2026.
- Integration, restructuring and deal costs were $806 million in FY2026, double the $403 million in FY2025.
- Total net income fell to $1,145 million in FY2026 from $1,678 million in FY2025.
10What to watch next
What should you watch next at Becton Dickinson?
Next event
Q1 FY2027 results
Date not announced yet.
Investor Day on Dec 10, 2026
BD said in its Q4 FY2026 release that it will hold an Investor Day at the New York Stock Exchange on Dec 10, 2026.
FY2027 results against guidance
BD said on Nov 5, 2026 that it expects low single-digit revenue growth and adjusted diluted EPS of $13.10 to $13.30 in FY2027; it reported $12.70 for FY2026.
The audited FY2026 10-K
FY2026 figures on this page come from the unaudited Nov 5, 2026 release; the 10-K had not been filed by Nov 20, 2026.
Ethylene oxide appeal
BD's appeal of a trial-court ruling in the first ethylene oxide case (argued May 14, 2026; no judgment entered, per the Q3 FY2026 10-Q); about 435 suits were pending at Jun 30, 2026.
11Key dates
What are the key dates for Becton Dickinson?
| Event | Date | Source |
|---|---|---|
| Investor DayAt the New York Stock Exchange, the company said in its Q4 FY2026 release. | Q4 and full-year FY2026 earnings release (8-K Ex. 99.1) |
12Key facts
Key facts about Becton Dickinson
- What does Becton Dickinson do?
- Becton, Dickinson and Company (BD) makes single-use medical supplies such as syringes, IV catheters and blood-collection tubes, plus infusion pumps and medicine-dispensing cabinets. BD's revenue was $19,457 million in FY2026, the year ended Sep 30, 2026 (unaudited).
- How does Becton Dickinson make money?
- Becton Dickinson earned 34.5% of FY2026 revenue from Medical Essentials ($6,703 million), 28.6% from Interventional, 24.4% from Connected Care and 12.5% from BioPharma Systems, which sells prefillable syringes to drug companies.
- Who are Becton Dickinson's customers?
- Becton Dickinson sells to hospitals, health systems, labs, distributors and drug companies. No customer was 10% or more of BD's revenue in FY2023, FY2024 or FY2025, and US customers paid 62% of FY2026 revenue.
- How big is Becton Dickinson?
- Becton Dickinson had FY2026 revenue of $19,457 million and net income from continuing operations of $1,417 million (unaudited). Total FY2026 net income was $1,145 million, including a $271 million loss from the business spun off to Waters.
- Who owns Becton Dickinson?
- Becton Dickinson has one class of shares and no controlling holder. Its directors and executive officers held 1,134,105 shares, under 1%, at Dec 1, 2025 (2026 proxy), and The Vanguard Group reported 11.3% as of Jun 30, 2025.
- What happened to Becton Dickinson's diagnostics business?
- Becton Dickinson combined its Biosciences and Diagnostic Solutions business with Waters on Feb 9, 2026. BD received $4 billion in cash, and BD shareholders received 39.2% of the combined Waters on a fully diluted basis.
- How much debt does Becton Dickinson have?
- Becton Dickinson had $16,345 million of debt and $725 million of cash at Sep 30, 2026, down from $19,179 million of debt a year earlier.
- Does Becton Dickinson pay a dividend?
- Becton Dickinson paid a quarterly dividend of $1.05 a share in FY2026, up from $1.04, and paid $1,161 million of dividends in FY2026.
Terms on this page
- Capital expenditures (capex)
- Debt-to-equity
- Earnings per share (EPS)
- EBITDA
- Free cash flow
- Interest coverage
- Net debt
- Net margin
- Revenue vs net income
- Stock buyback
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
13What it sells
13What it sells
What does Becton Dickinson sell?
Medical Essentials
Syringes, needles, IV catheters and blood-collection tubes for hospitals and labs: $6,703 million, the largest segment in FY2026.
Connected Care
Alaris infusion pumps, Pyxis medicine-dispensing cabinets, pharmacy robots and patient monitors bought from Edwards Lifesciences in 2024: $4,745 million in FY2026.
BioPharma Systems
Prefillable syringes sold to drug companies, which fill them with drugs such as GLP-1 weight-loss and diabetes treatments: $2,437 million in FY2026.
Interventional
Hernia mesh, ChloraPrep skin antiseptic, balloons and stents for blood vessels, and urology catheters: $5,573 million in FY2026.
Think of it like this
Much of it works like a razor-blade business: a hospital that installs BD pumps and cabinets keeps buying the disposable sets and supplies used with them.
What it does
- Does: Makes single-use syringes, needles, IV catheters and blood-collection tubes
- Does: Sells and leases equipment for giving and dispensing drugs
- Does: Supplies drugmakers with syringes for their injectable medicines
What it does not do
- Does not: No longer sells lab research instruments or diagnostic tests: that business went to Waters on Feb 9, 2026
- Does not: No longer sells diabetes injection products: Embecta was spun off on Apr 1, 2022
- Does not: Does not make the drugs that drugmakers put in its prefillable syringes
14How the money flows
14How the money flows · FY2026
How does money flow through Becton Dickinson?
Money in
- Revenue$19.5B
- Interest income and other income$113M
The company
Becton Dickinson
$19.6B came in
Money out
- Cost of making products$10.2B
- Selling and administration$5.0B
- Research and development$988M
- Integration, restructuring and deal costs$806M
- Other operating expenses$199M
- Interest on debt$564M
- Income tax$388M
- Net income from continuing operations$1.4B
- Hospitals, distributors, labs and drugmakers paid BD $19,457 million in FY2026.
- Making the products took $10,243 million, and selling them $4,965 million.
- Research, the cost of separating from the Waters business and other items took $1,993 million more.
- After $564 million of interest and $388 million of tax, $1,417 million was left from continuing operations.
15What it needs to run
15What it needs to run
What does Becton Dickinson need to run?
Factories in many countries
At Sep 30, 2025 BD had plants in 18 countries outside the US, from Mexico and Ireland to India and Singapore.
Sterilization
Many products are sterilized with ethylene oxide gas at BD sites and at outside firms; its Covington, Georgia site is the subject of lawsuits.
Single-source materials
Some raw materials and parts come from one supplier; switching can take 3 to 18 months, or 1 to 3 years if clinical trials are needed.
FDA clearances
Devices need clearance before sale; its updated Alaris infusion pump received FDA 510(k) clearance, the route for devices similar to ones already sold, on Jul 21, 2023.
People
More than 60,000 employees after the Waters deal, against about 72,000 in 61 countries at Sep 30, 2025.
16Where it sells
16Where it sells · FY2026
Where does Becton Dickinson sell?
- United States62%
- International38%
17Where growth could come from
17Where growth could come from
Where could Becton Dickinson's growth come from?
BD said on Nov 5, 2026 that it expects FY2027 revenue to grow at a low single-digit rate, both as reported and excluding currency, and adjusted diluted EPS (earnings per share, a non-GAAPThe company's own "adjusted" numbers, not the official (GAAP) ones. Always read them next to the official figure. Learn more measure) of $13.10 to $13.30.
Patient monitoring
Working+12.2% in FY2026
Advanced Patient Monitoring, bought from Edwards Lifesciences for $3.914 billion in Sep 2024, sold $1,215 million in FY2026, up from $1,082 million.
Status: Working, on track against what the company said.
Interventional products
Working+6.8% in FY2026
All three units grew: Peripheral Intervention 6.7%, Urology and Critical Care 7.4%, Surgery 6.4%.
Status: Working, on track against what the company said.
Syringes for GLP-1 drugs
Mixed+4.8% in FY2026
The Q3 FY2026 10-Q credits double-digit growth in syringes for biologic drugs, led by GLP-1 products, partly offset by lower vaccine demand.
Status: Mixed, partly on track.
Pharmacy automation
EarlyConnected Care +1.6% in Q4 FY2026
Fairview Health Services became the first US health system to deploy the BD Vmax 160 pharmacy robot; Connected Care grew 1.6% in Q4 FY2026.
Status: Early, too early to judge.
US manufacturing plan
New$19 billion planned
BD said on Nov 5, 2026 it intends to invest $19 billion in the US over several years, $3 billion of it in manufacturing, under a deal with the US government that gives tariff relief subject to milestones.
Status: New, recently announced.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
18The company's own measures (non-GAAP)
18The company's own measures · FY2026
What do Becton Dickinson's own measures show?
Official (GAAP): Diluted EPS from continuing operations, FY2026
$5.06
Company's own measure: Adjusted diluted EPS, FY2026
$12.70
BD leaves out items such as amortization of acquired intangible assets and integration, restructuring and transaction costs. Diluted EPS including the spun-off business was $4.09.
Official (GAAP): Diluted EPS from continuing operations, Q4 FY2026
$2.52
Company's own measure: Adjusted diluted EPS, Q4 FY2026
$4.15
Same adjustments as the full year; a year earlier the figures were $3.26 adjusted and $1.20 GAAP.
Official (GAAP): Diluted EPS from continuing operations, FY2025 (recast)
$3.81
Company's own measure: Adjusted diluted EPS, FY2025 (continuing operations)
$11.90
Recast without the business spun off to Waters, as the company presented it in its Q4 FY2026 release.
These are the company's own measures, defined by the company. They are not comparable across companies, and they are not added together. Each sits beside the nearest official (GAAP) figure.
Learn: Non-GAAP measures: what a company's "adjusted" numbers leave out
19Financial strength and debt
19Financial strength · Sep 30, 2026
How much debt does Becton Dickinson have?
- Total debt$16.3B
- Cash and investments$733M
- Net debt (debt minus cash)$15.6B
- Net worth (shareholders' money)$24.7B
- Debt to equity
- 0.66×
- $ of debt for every $1 of shareholders' money
- Interest cover
- 4.2×
- how many times operating profit covers interest
- Net debt (debt minus $725 million cash and $8 million short-term investments; restricted cash left out), debt-to-equity, interest cover (operating income of $2,257 million divided by interest expense net of interest income, $537 million) and years of cash flow are Cityfort calculations from the Q4 FY2026 earnings release, which is unaudited.
- About $2 billion of the $4 billion cash BD received in the Waters deal went to repaying debt (Q3 FY2026 10-Q).
- BD has a $2,750 million revolving credit line to Sep 2030; its loan terms cap leverage (debt measured against earnings) at 4.25 times (Q3 FY2026 10-Q).
20Who owns it
20Who owns it · ownership as of Dec 8, 2025
Who owns Becton Dickinson?
- Officers and directors (as a group), shares
- 0.4%
Share classes
Holders of 5% or more
From the company's proxy statement (DEF 14A), later Schedule 13G filings and the share counts on its latest annual or quarterly report. Each holder row shows the date of its own filing.
Learn: How to read a proxy statement (DEF 14A): Nvidia's 2026 proxy · Form 4 insider filings: who files, the codes and the footnotes
21What it does with profit
21What it does with profit
What does Becton Dickinson do with its profit?
Dividend per share
$4.16FY2025
Dividend paid for each share, by financial year.
$ per share
See the numbers
Buyback · Sep 30, 2024
Bought back $500 million of shares in FY2024.
$500M
Buyback · Sep 30, 2025
Bought back $1,000 million of shares in FY2025.
$1.0B
Buyback · Sep 30, 2026
Bought back $2,433 million of shares in FY2026, including a $2 billion accelerated buyback paid for with cash from the Waters deal.
$2.4B
22Governance signals
22Governance signals
What do Becton Dickinson's governance filings show?
- Auditor
- Ernst & Young LLP, since 1959
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- The 2026 proxy says BD had no related person transactions under its approval policy in FY2025.
- Credit rating
- S&P Global Ratings, Moody's and Fitch (as stated in the FY2025 10-K) BBB (S&P) / Baa2 (Moody's) / BBB (Fitch) (outlook Stable), Sep 30, 2025
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
regulatory
Infusion pumps under an FDA consent decree
A consent decree (a court-backed agreement with the FDA) has covered the infusion pumps made by its CareFusion 303 unit since 2009. The updated BD Alaris pump was cleared to return to market on Jul 21, 2023.
regulatory
Two FDA warning letters since 2024
The FDA sent a warning letter on the San Diego dispensing (Pyxis) site in Nov 2024 and one on the El Paso plant on Apr 30, 2026. BD says the 2024 commitments are complete and it has answered the 2026 letter.
other
Chairman is also the CEO
Tom Polen is Chairman, CEO and President. The board names a Lead Director when the Chairman is not independent; 12 of 13 director nominees were independent in the 2026 proxy.
disclosure
FY2026 not yet audited
The FY2026 10-K had not been filed by Nov 20, 2026, so the FY2026 figures here come from the unaudited Nov 5, 2026 earnings release. No earnings-call transcripts are held for this page.
23How it got here
23How it got here
How did Becton Dickinson get here?
1897
Milestone
Started in New York
BD began as a New York business and was incorporated in New Jersey in Nov 1906.
2020
Milestone
Tom Polen becomes CEO
Polen took over as CEO in early 2020 and added the Chairman role in Apr 2021.
2022
Business-model change
Diabetes business spun off
BD separated its Diabetes Care business as Embecta Corp. on Apr 1, 2022.
2023
Crisis
Alaris pump returns to market
The FDA cleared the updated BD Alaris infusion system on Jul 21, 2023, allowing it back on the US market after a long fix.
2024
Milestone
Bought Edwards Critical Care
BD paid $3.914 billion for Edwards Lifesciences' Critical Care group on Sep 3, 2024 and renamed it Advanced Patient Monitoring.
2025
Business-model change
Waters deal agreed
In Jul 2025 BD agreed to spin off its Biosciences and Diagnostic Solutions business and combine it with Waters.
2026
Business-model change
Spin-off completed
The Waters deal closed on Feb 9, 2026; BD received $4 billion, used for a $2 billion buyback and $2 billion of debt repayment.
2026
Milestone
US investment plan
On Nov 5, 2026 BD announced a plan to invest $19 billion in the US over several years.
Sources (6)
- Form 10-K for FY2025
- Proxy statement (DEF 14A) for the 2026 annual meeting
- Form 10-Q for Q3 FY2026
- 8-K filed Jul 14, 2025: agreement to combine Biosciences and Diagnostic Solutions with Waters
- 8-K filed Feb 9, 2026: completion of the Biosciences and Diagnostic Solutions combination with Waters (Ex. 99.1)
- Q4 and full-year FY2026 earnings release (8-K Ex. 99.1)
24Sources and changes
Where every number on this page comes from
Sources (25 documents)
- S1Form 10-Q for Q3 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Aug 6, 2026
- S2Form 10-Q for Q2 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · May 7, 2026
- S3Form 10-Q for Q1 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Feb 9, 2026
- S4Form 10-K for FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Nov 25, 2025
- S5Form 10-Q for Q3 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Aug 7, 2025
- S6Form 10-Q for Q2 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · May 1, 2025
- S7Form 10-Q for Q1 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Feb 6, 2025
- S8Form 10-K for FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Nov 27, 2024
- S9Form 10-Q for Q3 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Aug 1, 2024
- S10Form 10-Q for Q2 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · May 2, 2024
- S11Form 10-Q for Q1 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Feb 1, 2024
- S12Form 10-K for FY2023 · SEC EDGAR · Tier 1: company or exchange filing · Nov 21, 2023
- S13Form 10-K for FY2022 · SEC EDGAR · Tier 1: company or exchange filing · Nov 22, 2022
- S14Form 10-K for FY2021 · SEC EDGAR · Tier 1: company or exchange filing · Nov 24, 2021
- S15Proxy statement (DEF 14A) for the 2026 annual meeting · SEC EDGAR · Tier 1: company or exchange filing · Dec 18, 2025
- S16Q4 and full-year FY2026 earnings release (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Nov 5, 2026
- S17Q3 FY2026 earnings release (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Aug 6, 2026
- S18Q2 FY2026 earnings release (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · May 7, 2026
- S19Q1 FY2026 earnings release (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Feb 9, 2026
- S208-K filed Apr 2, 2026: recast quarterly results for continuing operations after the Waters spin-off (Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Apr 2, 2026
- S218-K filed Feb 9, 2026: completion of the Biosciences and Diagnostic Solutions combination with Waters (Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Feb 9, 2026
- S228-K filed Jul 22, 2026: officer retirement (Item 5.02) · SEC EDGAR · Tier 1: company or exchange filing · Jul 22, 2026
- S238-K filed Jul 14, 2025: agreement to combine Biosciences and Diagnostic Solutions with Waters · SEC EDGAR · Tier 1: company or exchange filing · Jul 14, 2025
- S24Schedule 13G, State Street Corporation (5.4% as of Jun 30, 2026) · SEC EDGAR · Tier 1: company or exchange filing · Aug 7, 2026
- S25Schedule 13G, First Eagle Investment Management (5.1% as of Jun 30, 2026) · SEC EDGAR · Tier 1: company or exchange filing · Aug 6, 2026
Changes to this page (v1 · Nov 20, 2026)
- v1 · Nov 20, 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.